

AMENDMENTS TO THE CLAIMS

1-30. **Cancelled**

31. **(Currently Amended)** An antigenic fragment of the human Factor VIII polypeptide, said fragment comprising at least 7 amino acids of a human Factor VIII fragment selected from the group consisting of a human Factor VIII fragment contained between arginine 1652 and arginine 1696 inclusive, ~~a human Factor VIII fragment contained between threonine 1739 and aspartic acid 1831 inclusive~~, and a human Factor VIII fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

32. **(Currently Amended)** The antigenic polypeptide according to Claim 31, wherein said human Factor VIII fragment comprises an epitope selected from the group consisting of: a human Factor VIII fragment contained between arginine 1652 and tyrosine 1664 (SEQ ID No: 1), a human Factor VIII fragment contained between threonine 1739 and tyrosine 1748 (SEQ ID No: 3), a human Factor VIII fragment contained between asparagine 1777 and phenylalanine 1785 (SEQ ID No: 4), ~~a human Factor VIII fragment contained between glutamic acid 1794 and tyrosine 1815 (SEQ ID No: 5), a human Factor VIII fragment contained between methionine 1823 and aspartic acid 1831 (SEQ ID No: 6)~~, a human Factor VIII fragment contained between glutamic acid 1885 and phenylalanine 1891 (SEQ ID No: 7), a human Factor VIII fragment contained between glutamic acid 1893 and alanine 1901 (SEQ ID No: 8), and a human Factor VIII fragment contained between aspartic acid 1909 and arginine 1917 (SEQ ID No: 9).

33. **(Previously Amended)** The antigenic polypeptide according to Claim 31, wherein said antigenic polypeptide comprises tyrosine or histidine.

34. **(Previously Amended)** A conformational epitope containing at least two different human Factor VIII fragments of Claim 32, wherein said fragments are positioned in proximity to each other when the protein is folded in its tertiary or quaternary structure to form a conformational epitope which is recognized by an inhibitor of Factor VIII selected from the group consisting of B lymphocytes, MHC I proteins, MHC II proteins, and anti-Factor VIII antibodies.

35. **(Previously Amended)** A conformational epitope containing at least two different epitopes from a human Factor VIII fragment selected from the group consisting of a human Factor VIII fragment contained between arginine 1652 and arginine 1696 inclusive, a human Factor VIII fragment contained between threonine 1739 and aspartic acid 1831, inclusive, and a human Factor VIII fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

36. **(Currently Amended)** A complex, comprising a carrier protein or a carrier peptide linked to the ~~antigenic~~ polypeptide of Claim 31 or the conformational epitope of Claim 35, ~~whereby~~ wherein said complex ~~increases~~ has higher immunogenicity than said polypeptide of Claim 31.

37-38. **(Cancelled)**

39. **(Previously Amended)** A pharmaceutical composition comprising at least the antigenic polypeptide of Claim 31, or the conformational epitope of Claim 35 and an acceptable pharmaceutical vehicle.

40-43. **(Canceled)**

44. **(New)** The complex of Claim 36, wherein said carrier protein or said carrier peptide are bovine serum albumin or hemocyanin.

45. **(New)** A polypeptide consisting of a human Factor VIII fragment selected from the group consisting of a human Factor VIII fragment between arginine 1652 and arginine 1696 inclusive, a human Factor VIII fragment between threonine 1739 and aspartic acid 1831 inclusive, and a human Factor VIII fragment between glutamic acid 1885 and arginine 1917 inclusive, and a fragment comprising at least 7 amino acids thereof, wherein said polypeptide is antigenic.

46. **(New)** The polypeptide according to Claim 45, wherein said human Factor VIII fragment consists of an epitope selected from the group consisting of: a human Factor VIII fragment contained between arginine 1652 and tyrosine 1664 (SEQ ID No: 1), a human Factor VIII fragment contained between threonine 1739 and tyrosine 1748 (SEQ ID No: 3), a human Factor VIII fragment contained between asparagine 1777 and phenylalanine 1785 (SEQ ID No: 4), a human Factor VIII fragment contained between glutamic acid 1794 and tyrosine 1815 (SEQ